OncoMatch/Clinical Trials/NCT06922318

The COSMYC Trial (COmbined Suppression of MYC)

Is NCT06922318 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including ZEN-3694 and Testosterone cypionate for metastatic castration-resistant prostate cancer.

Phase 2RecruitingSidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06922318Data as of May 2026

Treatment: ZEN-3694 · Testosterone cypionate · Enzalutamide · Luteinizing hormone-releasing hormone (LHRH) analogue — This research is being done to determine if receiving the combination of testosterone and ZEN-3694 followed by the combination of enzalutamide plus ZEN-3694 will decrease the size of tumors in patients with prostate cancer that has become resistant to castration and other therapies. The investigators also want to determine if dosing first with the combination of testosterone and ZEN-3694 may cause enzalutamide and ZEN-3694 to work more effectively.

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Disease stage

Metastatic disease required

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Must have received: androgen deprivation therapy (surgical castration, LHRH agonist, LHRH antagonist) — continuous

Treated with continuous androgen ablative therapy (either surgical castration or LHRH agonist/antagonist)

Must have received: second-generation AR-axis inhibitor (abiraterone, enzalutamide, darolutamide, apalutamide)

Must have had disease progression while on a second-generation AR-axis inhibitor (Abiraterone, Enzalutamide, Darolutamide, or Apalutamide)

Lab requirements

Blood counts

ANC ≥ 1000 cells/mm3; Platelet count ≥ 100,000/mm3; Hemoglobin ≥ 7.5 g/dL

Kidney function

Serum creatinine <2.5x ULN

Liver function

Bilirubin < 2.5x ULN; AST and ALT < 2.5x ULN

Acceptable liver function: Bilirubin < 2.5x ULN; AST and ALT < 2.5x ULN. Acceptable renal function: Serum creatinine <2.5x ULN. Acceptable hematologic status: ANC ≥ 1000 cells/mm3; Platelet count ≥ 100,000/mm3; Hemoglobin ≥ 7.5 g/dL.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center · Baltimore, Maryland

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify